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Estrogen receptor β (ESR2) shares a structural homology at the DNA and ligand binding 
domains (96% and 58%, respectively) with estrogen receptor α (ESR1), the major type of 
estrogen receptor in breast cancer (1, 2). Similarities notwithstanding, ESR2 has functions and 
expression patterns distinct from ESR1, and is widely expressed in both basal and luminal 
epithelial cells (3-6). The exact role of ESR2 in breast cancer is not clear, with both anti-
proliferative and proliferative roles being described (7, 8). The mechanisms for these opposing 
actions of ESR2 in breast tumorigenesis have not been fully elucidated; this in part due to 
different isoforms and binding partners. 
In this issue of the Journal, Mukhopadhyay et al. (9) provide a mechanistic explanation 
for the plastic nature of ESR2 function in triple negative breast cancer (TNBC) related to its 
interactions with TP53 status (wild type or mutant). In wild type TP53-expressing cells, silencing 
of ESR2 augmented apoptosis, while its overexpression resulted in increased proliferation. 
Opposite effects were observed following silencing or overexpression of ESR2 in mutant TP53 
cells, suggesting the important role of TP53 status in determining ESR2’s function. 
Mechanistically, ESR2-mutant TP53 interaction mediates sequestration of mutant TP53 leading 
to the TP73 activation and anti-proliferative effects. Treatment with tamoxifen (4-hydroxy 
tamoxifen) also increases ESR2 expression and reactivates TP73 in mutant TP53 cells providing 
an explanation for its beneficiary effects. Analysis of the METABRIC TNBC subgroup of basal-
like tumors (n=259), based on ESR2 levels and TP53 mutation status confirmed the impact of 
these interactions on survival, i.e. mutant TP53 -expressing tumors with high ESR2 levels have 
better survival. 
 The strengths of this study include provision of a mechanistic understanding for the dual 
role of ESR2 in breast cancer based on TP53 mutational status with further validation of the 
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djz052/5452445 by IU
PU
I U
niversity Library user on 30 April 2019
3 
 
hypothesis in clinical cohorts. Considering that basal-like TNBC cases are enriched in TP53 
mutations (10), Mukhopadhyay et al. (9) suggests that the company of ESR2 with mutant TP53 
can prognosticate TNBC patients and more importantly help select a population for tamoxifen 
therapy. The beneficial effects of endocrine therapy in unselected ESR1-negative breast cancer 
and TNBC cohorts have been previously described (11-14). The ability to selectively administer 
endocrine therapy should, in principle, lead to greater response rates. It is unclear what the 
impact of ESR2-TP53 interactions have in ER+ breast cancer, particularly since all patients are 
offered endocrine therapy.  
Many tumor related genes have been documented to have a dualistic nature being 
associated with progression in some but not all cancers. The opposing effects exist for many 
biomarkers even within the same cancer as in the case of ESR2 in breast cancer. Understanding 
the molecular basis of this phenomenon, although not always possible, is a laudable goal. A 
number of different mechanism have been described to explain the duality of protein function. 
The first and foremost is the tissue type. The cellular milieu of different organs is distinct and the 
role that individual pathways play in maintaining of cellular phenotype can be dramatically 
different. This is at least in part the explanation offered to explain the tissue specific impact of 
mutations in BRCA1, a gene involved in DNA repair. Mutations can also lead to altered splicing 
pattern or post translational modifications resulting in mislocalization of proteins and acquisition 
of novel functionality. Abnormal nuclear localization of EGFR, and MUC1 and cytoplasmic 
localization of BRCA1, and TP53 has been described in breast cancer and represents good 
examples for this concept (15); these maybe due to mutations in the gene itself or its binding 
partners. Duality of function can be also induced by splicing factors inducing alternative 
transcripts of the gene as illustrated by progesterone A and B isoforms in breast cancer. 
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Mutations can lead to constitutive activation or suppression of function. Mutations leading to 
stabilized mutant TP53 proteins may simultaneously gain novel functions, primarily through 
protein–protein interactions with other transcription factors (TFs) within the cellular 
neighborhood (16). Proteins that partner with mutant TP53 may transactivate or disrupt target 
gene activation with consequent changes in cellular function, suggesting the importance of the 
neighborhood actors. Epithelial Splicing Regulatory Protein (ESRP1), a splicing factor, exhibits 
a dual role based on the tissue and cancer type (17). Low ESRP1 expression has been associated 
with the development of epithelial to mesenchymal transformation (EMT) by alternative splicing 
in ER- negative breast cancer models (MDA-MB-231 cells) (18, 19). In contrast, knockdown of 
ESRP1 in ER+ models did not result in development of mesenchymal phenotype (16). This may 
be due to lack of key EMT transcription factors in ER+ breast cancer, suggesting that company 
matters. 
Beyond the obvious, the current study has broader implications. It documents the 
important principle of “company matters” in understanding the impact of markers and mutations 
in cancers, including breast cancer. The intracellular environment is a complex milieu wherein 
changes in one player can have a dramatic impact on DNA, RNA and protein interactions. The 
players in the neighborhood could further affect cellular phenotype. Acknowledging these 
processes also provides a reality check for those of us involved in precision medicine, wherein 
treatments are being prescribed based on the presence of single gene mutations (20). The 
cooperativity and interactions of cellular networks may, to a large extent, determine the 
prognostic and predictive utility of mutations in patients. The study by Mukhopadhyay et al (8) is 
a good step in this direction and provides compelling reasons to understand the combinatorial 
impact to determine clinically actionable strategies and solutions. 
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